SLC16A1 and central nervous system cancer: A recent study revealed that the mRNA level of SLC16A1 was significantly increased in high-grade gliomas compared to LGG and non-tumor controls, suggesting that SLC16A1 expression is positively correlated with WHO pathological grading and poor survival of gliomas [34].